Is the PolyNovo share price in the buy zone?

The PolyNovo Ltd (ASX: PNV) share price closed yesterday's trading session more than 8% higher and could be in the buy zone for 2020.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The PolyNovo Ltd (ASX: PNV) share price closed yesterday's trading session more than 8% higher. Although there was no direct catalyst to prompt the share price move, it could be an indication of continued interest in the company.

What does PolyNovo do?

PolyNovo is an Australian-based medical technology company that designs, develops and manufactures dermal regeneration solutions. The company is based around CSIRO medical technology developed following the Bali bombings as an alternative to animal-based products.

PolyNovo's flagship NovoSorb Biodegradeable Temporising Matrix (BTM) product is a biodegradable polyurethane-based polymer that helps the body use its own systems to repair damaged tissue. NovoSorb acts as a dermal scaffold and is then broken down into carbon dioxide and lactic acid, which is excreted through urine. NovoSorb's cutting-edge technology was displayed recently during theWhite Island volcano tragedy in New Zealand.  

NovoSorb is currently marketed in Australia, New Zealand and the US, with PolyNovo recently obtaining licencing approval for the UK and the European Union.

How did PolyNovo perform in 2019?

The PolyNovo share price surged in 2019, closing more than 230% higher for the year and hitting all-time highs. PolyNovo also reported strong full-year earnings for FY19, with the company reporting a revenue increase of 128% from the previous year of $13.68 million. Revenue growth was fuelled by a 435% increase in sales revenue of NovoSorb, which clocked in at $9.3 million for the year.  

PolyNovo was awarded for its stellar performance with the company being an addition to the S&P/ASX 200 (INDEXASX: XJO) in the September quarterly rebalance. Inclusion in the ASX 200 opens additional avenues of growth for the PolyNovo share price as index funds look to get involved.

Should you buy?

I don't usually advocate buying shares in a company that has experienced a meteoric rise like PolyNovo. However, the growth prospects are tremendous for the company. PolyNovo is well positioned in key markets, especially the US with rapid expansion of its sales team. In addition, licencing approval for access to addressable markets in the UK and European Union offers excellent growth potential. This potential was reflected at the PolyNovo AGM late last year, when the company's management informed shareholders that its was on track to double sales revenue for NovoSorb in FY20.

PolyNovo's addition to the ASX 200 provides the company with favourable exposure to index funds and larger institutional investors. The company is also in the process of developing a variety of products that address hernia's, breast reconstruction and various other skin technologies.

I think that PolyNovo is an exciting company with excellent growth prospects. A prudent strategy would be to keep PolyNovo on a watchlist and wait for positive price action before making an investment decision.

Another ASX-listed skin specialist to add to your watchlist is Avita Medical Limited (ASX: AVH), which was co-founded by plastic surgeon and former Australian of the Year, Dr Fiona Wood AM, who is also director of the Royal Perth Hospital burns unit and the Western Australia Burns Service.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Woman with a scared look has hands on her face.
Share Fallers

These were the worst performing ASX 200 shares in July

Let's see why investors were selling off these shares last month.

Read more »

A team of people giving the thumbs up sign representing APA and Wesfarmers doing a deal to study green hydrogen transport using an APA gas pipeline
Broker Notes

9 ASX 200 shares attracting 'strong buy' ratings from the experts

There is a consensus 'strong buy rating' on these stocks from analysts on the CommSec trading platform.

Read more »

A cute little kid in a suit pulls a shocked face as he talks on his smartphone.
Broker Notes

What does Macquarie expect from Telstra shares this earnings season?

Telstra shares are up 22% so far in 2025.

Read more »

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing end to the trading week this Friday.

Read more »

A woman reaches her arms to the sky as a plane flies overhead at sunset.
Broker Notes

Macquarie predicts 25% upside for Flight Centre shares

Flight Centre shares have had a bumpy ride in 2025, but Macquarie sees clear skies ahead.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Opinions

Should you hold on to these 4 ASX 200 outperformers or take your profits and run?

Should you hold on to these ASX stocks after outstanding growth or take your profits and run?

Read more »

Young people shopping in mall and having fun.
Broker Notes

7 ASX retail shares to buy as Aussies start spending again: experts

The Australian Bureau of Statistics reported a 'retail sales surge' in June with 1.2% higher turnover.

Read more »

Miner and company person analysing results of a mining company.
Broker Notes

Why Macquarie just raised its price target for Rio Tinto shares

Macquarie offers its verdict on Rio-Tinto shares following the half-year results.

Read more »